Type 2 diabetes is a chronic metabolic disorder that affects millions worldwide and is frequently associated with obesity, cardiovascular disease, and other metabolic complications. Recent advances in diabetes management have shifted the focus beyond glycemic control toward comprehensive cardiometabolic risk reduction and long-term patient outcomes. Semaglutide, a GLP-1 receptor agonist, has emerged as a key therapeutic option due to its proven efficacy in lowering HbA1c, promoting weight loss, and improving cardiovascular health.
Growing clinical evidence continues to support its role in modern diabetes care, making it an important consideration for healthcare professionals managing patients with type 2 diabetes. To learn more about the evolving role of semaglutide in diabetes management, join renowned physician Prof. Narsingh Verma in our informative webinar on 09 July 2026, 1:00 PM…
